Home › Studies › PRJEB44907
PRJEB44907 ERP129009

Berberine/Bifidobacterium gut microbiota in hyperglycemia (China)

Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: A multi-center, double-blind, randomized, parallel-controlled study

Multi-centre, double-blind randomised trial of berberine and/or Bifidobacterium in adults with hyperglycaemia in Shaanxi, China: 208 stool shotgun metagenomes from 104 participants (two samples each). machine-written summary

208 samples · 208 runs · CN · Age unknown · 2021 · 2.99 Gbp / sample

Sources
✓Sequence archive 624○Abstract / description○Full text○Supplementary tables–External resources–User contribution–Human verified

Checked this project's papers and archive records yourself? Mark it human-verified.

what each source gave
✓ Sequence archive624 sample values (collection date, country, subject id)
○ Abstract / descriptionread; no usable statement
○ Full textread; no usable statement or table · PMC8351344
○ Supplementary tablesfiles read; no table could be matched to the samples
– External resourcesnot covered by the external resources we ingest
– User contributionnothing uploaded yet · share metadata
– Human verifiednot yet checked by a person · I checked this project — verify it
Interventions

intervention — arms not resolved

Non-antibiotic pharmaceutical given as the study intervention (metformin Probiotic (live microorganisms; single strain or mixture) design randomized_controlled_trial · population type2_diabetes · Berberine and/or Bifidobacterium vs placebo, 16-week RCT

“randomized, double-blind, parallel-controlled study of patients newly diagnosed with hyperglycemia” — abstract:34365978 (study level; per-sample arms are in the intervention column below)

Samples at a glance
1 country
Age
unknown208
Country
CN208
Body site
primary208
Collected 2016–2018
2016: 99 samples2017: 89 samples2018: 20 samples20162018
Sequencing depth per sample · this project all projects
all projects, 0–0.03 Gbp: 25,080 samples (4 %)all projects, 0.03–0.1 Gbp: 17,066 samples (3 %)all projects, 0.1–0.3 Gbp: 29,179 samples (5 %)all projects, 0.3–1 Gbp: 47,044 samples (8 %)this project, 0.3–1 Gbp: 2 samplesall projects, 1–3 Gbp: 124,983 samples (22 %)this project, 1–3 Gbp: 206 samplesall projects, 3–10 Gbp: 253,728 samples (44 %)all projects, 10–30 Gbp: 72,533 samples (13 %)all projects, 30–100 Gbp: 3,024 samples (1 %)all projects, 100–300 Gbp: 106 samples (0 %)all projects, ≥ 300 Gbp: 9 samples (0 %)project median 2.99 Gbp per sample0130Gbp
Sampling design and relatedness

longitudinal

104 of 104 people sampled more than once (208 samples; median 2, up to 2 per person) · follow-up median 4 mo (max 9 mo) · median interval between samples 4 mo (time from collection dates). Schedule stated by the source: “baseline (post run-in) and after 16 weeks of treatment” (time origin: unknown).

010007010007: day 0010007: day 125010008010008: day 0010008: day 117010013010013: day 0010013: day 118010016010016: day 0010016: day 83010019010019: day 0010019: day 107010023010023: day 0010023: day 126010027010027: day 0010027: day 125010029010029: day 0010029: day 112010037010037: day 0010037: day 112010044010044: day 0010044: day 137010046010046: day 0010046: day 111010049010049: day 0010049: day 50010054010054: day 0010054: day 112010063010063: day 0010063: day 112010068010068: day 0010068: day 111010069010069: day 0010069: day 113010070010070: day 0010070: day 125010074010074: day 0010074: day 111010090010090: day 0010090: day 112010095010095: day 0010095: day 113010096010096: day 0010096: day 120010102010102: day 0010102: day 112010104010104: day 0010104: day 111030005030005: day 0030005: day 111030006030006: day 0030006: day 111030008030008: day 0030008: day 112030012030012: day 0030012: day 111030016030016: day 0030016: day 112030025030025: day 0030025: day 112030033030033: day 0030033: day 111030037030037: day 0030037: day 112030040030040: day 0030040: day 111030041030041: day 0030041: day 114030055030055: day 0030055: day 111030056030056: day 0030056: day 110030059030059: day 0030059: day 1100 d34 d2 mo3 mo5 mo

Each row is one person (36 shown of 104); dots are samples at days since that person's first sample.

How longitudinal and relatedness information is derived

Community composition

No Sandpiper profile for this project's samples yet.

Field coverage
fieldsamplescoverageR1R2R3R4
age_category0 0%
country208 100%208
health_condition0 0%
subject_id208 100%208
collection_date208 100%208
Papers (1)
  • Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study. 2021 PMID 34365978 PMC8351344 own_data
Details
Archive description

Berberine and Bifidobacterium have been reported to improve glucose tolerance in people with hyperglycemia or other metabolic disorders. This study aimed to assess the hypoglycemic effect of berberine’s and Bifidobacterium’s hypoglycemic effect and regulation of the gut microbiota, and the possible additive benefits of combination.

How this project entered the registry

Classified as human gut / stool shotgun DNA metagenome of age unknown by curator_audit with confidence 0.50. Assay shotgun_dna.

  • host runs.scientific_name · “human gut metagenome”
  • host papers[0].abstract · “patients newly diagnosed with hyperglycemia”
  • body site runs.scientific_name · “human gut metagenome”
  • body site papers[0].abstract · “patients newly diagnosed with hyperglycemia”
Evidence examples (one per field × route)
samplefieldvaluerouteconf.sourcequote
SAMEA8740346collection_date2016-05-17R10.85biosample.attribute:collection_date2016-05-17
SAMEA8740346countryCNR10.90sample.attr.geographic_location_country_and_or_seaChina
SAMEA8740346subject_id010007R10.70sample.name_rule:sample_descriptS010007_T
Sequencing

208 runs over 208 samples · mean 2.91 Gbp per run (median 2.99 Gbp, total 604.98 Gbp; 208 runs with a base count) · layout PAIRED 208 · platform ILLUMINA 208 · models Illumina NovaSeq 6000 (208) · 91% of runs with a Sandpiper profile · first public 2021-05-13

Authors (0)

No author record.

Help complete this project

2 of the 4 core fields are below 50% coverage: age_category, health_condition. Share metadata

Downloads

PRJEB44907.csv.gz (6.3 KB) · parquet (77.8 KB) — all 208 samples, every field with route and confidence · PRJEB44907_determinations.csv.gz (6.3 KB) — 624 evidence rows

Samples (208 · every field this project has values for · hover a cell for its source)
Loading the sample table…